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Chris S. Haley1,2Abstract
The 10th anniversary ‘Genomics of Common Diseases’
meeting was held in Baltimore, September 25-28,
2016. Professor Chris Haley reports from the meeting
on progress and challenges in the field.lipoproteins. Rick Dewey (Regeneron Pharmaceuticals, Inc.,The first meeting in the Genomics of Common Diseases
series was held just after the publication of the first
successful genome-wide association analyses (GWAS),
when optimism for the genomic dissection of common
complex traits and diseases was high. Much progress has
been made in the intervening period, so the 10th meeting
provided a good opportunity to assess successes so far
and the path ahead. Here, I do not attempt to summarise
every presentation but rather to draw out some of the
important themes as I saw them.
The value of exome sequencing
The meeting was book-ended by presentations focusing on
the value of whole exome sequencing (WES). The first
Keynote speaker, Richard Lifton (The Rockefeller Univer-
sity, USA), illustrated the use of WES in the identification
of alleles with major effect with a number of examples. He
pointed out that almost all Mendelian conditions are
underpinned by variation in the exome and the proteins
thus affected are potential drug targets. He also commented
that whilst whole genome sequencing (WGS) provides
much more data, it also costs approximately four times
more than WES and the functional consequences of vari-
ation outside the exome are much more difficult to predict.
At the end of the meeting, two speakers highlighted the
value of WES in isolated populations for identification of
deleterious major mutations where recent population
bottlenecks and drift have led to enrichment of these typesCorrespondence: chris.haley@roslin.ed.ac.uk
1MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine,
University of Edinburgh, Edinburgh, UK
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Medicine, USA) reported analysis of data from 20,000
Finnish exomes which allowed the identification of many
rare variants associated with cardiometabolic traits. These
included premature stop, splice, frameshift and missense
variants associated with creatinine, adiponectin, ApoA1 and
USA) reported on his company’s efforts to exploit WES
from both cosmopolitan and isolate populations. Echoing
Professor Lifton’s arguments, their analysis of over 100,000
exomes found many such ‘natural experiments’, identifying
both harmful and protective genetic associations with
clinical traits, including variants in known drug targets.The UK Biobank
Whilst WES is proving invaluable for the identification of
individual Mendelian variants with large effects, the major
progress in detecting the heritable component of common
complex disease over the last 10 years has been through
the application of SNP genotyping arrays to GWAS using
large population samples. Until recently the largest sam-
ples have been accessed through meta-analysis, but in the
last year results from the first 150,000 genotyped individ-
uals from the UK Biobank have become available. These
latter data made a major contribution to the associations
identified for many haematological traits presented by Tao
Jiang (University of Cambridge, UK) and colleagues. The
UK Biobank was also one of several studies contributing
to the GWAS of reproductive ageing presented by John
Perry (University of Cambridge, UK), which also found
potentially causal associations of this trait with several
cancers including breast and prostate cancer.
Perhaps the most novel example of the traits explored by
GWAS that was presented at the meeting was from Cisca
Wijmenga (University of Groningen, Netherlands). She
demonstrated how careful analysis of the microbiome using
metagenomic sequencing of stool samples could be
combined with whole genome data to identify host factors
associated with the abundance of various microbial species.
Although as yet relatively modest in size compared tole is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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replicated and the study identified evidence of host-by-diet
interactions and suggestive associations with loci involved
in various traits and diseases.
The space between common and rare variants
Clearly, GWAS is effective at locating common variants of
small effect and WES is identifying de novo and very rare
variants of much larger effect. However, there appears to
be a gap in the spectrum of allele effect sizes between
these two types of study that represent variants that are
not yet effectively captured. Our own presentation at the
meeting explored the variation for quantitative traits and
diseases that is associated with SNPs and with pedigree.
We concluded that about half the variation was associated
with the genotyped SNPs and the remainder with genetic
variation within families that is not yet captured by SNPs,
even after accounting for family environmental effects. In
addition there was evidence for interactions between
genes and environment that might help to explain why
heritabilities from twins sharing common environments
seem consistently higher than those from other types of
families. It may be possible to increase the proportion of
variation captured by GWAS by incorporating informa-
tion from ever rarer SNPs. However, my own conclusion
is that individual rare variants with larger effects are likely
to be confined within families and kinships, with their
frequencies constrained to low frequencies by the impact
they have on fitness. This will necessitate an increased
focus on genetic variation associated with families and
isolate populations, rather than the unrelated samples
now commonly used.
Combining reference and local population samples
Whatever the population sampling strategy, the step
beyond SNP based studies of large population cohorts is
to complement these with sequence data from the exome
or the whole genome. As a first step this uses sequence
data from reference populations combined with SNP data
from the populations under study to impute ungenotyped
common and rare variants across the whole population.
Harm-Jan Westra (Harvard Medical School, USA) used
this approach to impute additional variants into regions
around loci previously detected in rheumatoid arthritis
and type 1 diabetes case-control cohorts. This allowed
them to conclude that there were multiple putative causal
variants in several of the loci and single putative causal
variants in just two of the loci.
Although this approach has proved successful in cosmo-
politan populations, it has become clear that individual
populations have their own rare variants that can only be
effectively imputed by combining reference population
with sequence data from local populations. Liping Hou
(National Institute of Mental Health, USA) and colleaguesillustrated this with whole genome sequence from 265
individuals from an Anabaptist reference sample. They
found a substantial number of variants not found in the
1000 genomes reference panel, with 43,000 variants that
were rare (<0.5%) in the panel but with frequencies above
5% in Anabaptists. Manuel Rivas (Broad Institute, USA)
described a similar situation in Ashkenazi Jews, where
exome sequencing revealed that many protein coding
alleles are enriched in this population. This includes 128
potentially pathogenic alleles which may contribute to
elevated levels of some diseases in Ashkenazi Jews, with
for example elevated frequencies of 11 risk variants
contributing an estimated 44% of the 4-fold increased risk
of Crohn’s disease in this population.Whole genome sequencing
Despite these and other successes, it is clear that ultim-
ately whole genome sequence from very large population
cohorts will be generated, necessitating step up in compu-
tational resource to deal with the massive data that will be
generated. Benjamin Neale (Massachusetts General Hos-
pital Research Institute, USA) described the Hail software
package that uses a distributed computing approach to
tackle this problem. He described the application of this
software to 14,000 individuals with exome or whole gen-
ome sequence data to identify a role for very rare disrup-
tive variants in educational attainment.
Gonçalo Abecasis (University of Michigan, USA) also
described software tools, in his case applied to the first
~50,000 whole genome sequences from the National
Heart, Lung and Blood Institutes TOPMed programme.
Results included the identification of 1.5 million putative
missense SNPs and 39,000 potential loss of function
SNPs in the first ~20,000 sequenced individuals. In a
follow-up discussion, he suggested that the 30x coverage
target is the result of multiple competing considerations,
including challenges in using the Illumina sequencing
platform efficiently at lower depths. In his view, an
optimum strategy for research studies is likely to se-
quence samples at lower depths and then fill any gaps
computationally.
One consequence of the various methods that increase
focus on rare variants is that individual variants may be
increasingly difficult to detect and replicate, especially
those confined to specific populations or kinships. Bogdan
Pasaniuc (University of California, Los Angeles, USA)
described applications combining summary GWAS
association statistics. One application, termed ‘local SNP
heritability’ combines information from multiple SNPs in
a region accounting for LD between them to produce a
composite signal that may contribute to alleviating this
problem, providing replication at the locus level rather
than the SNP variant level.
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The meeting gave several glimpses of where research might
be heading in the future. Eventually inroads will have to be
made into assigning function to the many thousands of
variants of small effect identified for hundreds of traits and
diseases by past and future GWAS, most of which are not
protein-coding. Michael Levine (Princeton University,
USA) pointed out that we should not assume that
enhancers are optimised to maximise expression. From
elegant work on sea squirts it was clear that there was a
balance between optimising expression and its tissue speci-
ficity, such that enhancers that maximised expression lost
some tissue specificity. This raises the possibility that both
increasing and decreasing enhancer activity could have
deleterious consequences.
Karen Mohlke (The University of North Carolina at
Chapel Hill, USA) gave examples of exploring candidate
SNPs for type 2 diabetes and cholesterol using high reso-
lution mapping combined with data on chromatin status
followed by in vitro functional assays to explore their effects
on expression. In one example the effects of one variant on
expression were consistent across models and with known
biology. But in a second several variants in a haplotype
seemed to show differential effects on expression, and
results had to be reconciled with apparently conflicting data
from the literature before the picture made sense.
In order to make substantial progress with this herculean
task it will be necessary to supplement detailed analysis of
individual associations with high throughput methods to
identify and test associations and their biological causation.
Olga Troyanskaya (Princeton University, USA) presented
work using the deep learning based ‘DeepSEA’ framework.
This algorithm attempts to learn the regulatory sequence
code from large-scale chromatin-profiling data and predict
the tissue specific chromatin effects of single nucleotide
variants in order to prioritise variants for follow-up.
Arjun Krishnan (from the Troyanskaya group) leveraged
information of the small proportion of loci known to be
associated with ASD in a machine learning approach that
harnessed a brain-specific gene-interaction network to
identify key pathways. Using this information they pre-
dicted novel loci associated with ASD and could validate
some of these in an independent sequencing study.
The group of Nancy Cox (Vanderbilt University School
of Medicine, USA) group is one of several that have re-
cently shown how GWAS associations with a trait can be
used to impute that trait into populations where the trait
is not recorded but whole genome SNP data is available.
In the examples she presented, gene expression was
imputed into the large BioVu cohort of individuals with
electronic health record data, enabling inference on the
potential association of locus expression with disease. For
example SLC39A4 is a zinc transporter and known
Mendelian loss of function variants in this locus lead tosevere inflammatory rash associated with zinc deficiency
that can be ameliorated by zinc supplementation.
Predicted variation in expression of this locus was associ-
ated with similar symptoms in patients not carrying
Mendelian loss of function variants, suggesting that zinc
supplementation might benefit some of these patients.
Consequently a “pragmatic trial” to test this hypothesis in
the patient cohort is underway. This study thus provides a
bridge showing how Mendelian variants, often driven by
exonic variation as noted right at the start of the meeting,
can help understand the impact of variants of smaller
effect typically identified by GWAS which lie outside of
the exome and have their impact via modulation of
transcription.
The final presentation in the meeting by Kiran Musunuru
(University of Pennsylvania, USA) gave a glimpse of how
potential causative variants might be assessed in future
using high-throughput phenotyping. He has used a CRISPR
based approach to generate all catalogued coding variants
in the cardiomyopathy-associated locus TNNT2. The aim
is to generate mutant cell lines and use gene expression
and phenotypic profiling to assess the pathogenicity of the
variants. This approach could be used in future to rapidly
assess novel patient-specific disease variants.
Conclusions
Much has been achieved in terms of understanding the
genetic basis of disease. But a great deal more remains
to be done if we are to understand and exploit the
underlying biological causes of all the associated variants
and turn this knowledge into treatments. The first steps
down this path have been taken and the meeting dem-
onstrated much optimism for the future; but in reality
we are only just reaching “the end of the beginning” with
many more challenges lying ahead.
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